Johan Abrahamsson
Malmoe, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.
Journal: JCO precision oncology
Published: September 30, 2024
Violation of onco-surgical principles is associated with survival outcomes in upper tract urothelial carcinomas after radical nephroureterectomy.
Journal: Scandinavian journal of urology
Published: November 13, 2023
Location of Retroperitoneal Lymph Node Metastases in Upper Tract Urothelial Carcinoma: Results from a Prospective Lymph Node Mapping Study.
Journal: European urology open science
Published: September 14, 2023
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
Journal: International journal of cancer
Published: May 09, 2023
FDG-PET/CT for lymph node staging prior to radical cystectomy.
Journal: European journal of hybrid imaging
Published: April 16, 2023
UROSCAN and UROSCANSEQ: a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice - from biobank to RNA-sequencing in real time.
Journal: Scandinavian journal of urology
Published: December 21, 2022
Urosymphyseal fistula after pelvic radiotherapy in a tertial referral centre - a rare entity with significant comorbidity requiring multidisciplinary management.
Journal: Scandinavian journal of urology
Published: December 11, 2022
Robot-assisted nephroureterectomy for upper tract urothelial carcinoma-feasibility and complications: a single center experience.
Journal: Scandinavian journal of urology
Published: June 23, 2022
Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer-A Narrative Review.
Journal: Cancers
Published: February 24, 2022
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
Journal: European urology
Published: December 15, 2021
Re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy Have Therapeutic Benefit for Node-positive Upper Tract Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In press. https://doi.org/10.1016/j.urolonc.2021.07.029: A Plea for Uniform Terminology for Patients with Urothelial Carcinoma Treated with Chemotherapy Before Consolidative Surgery with Curative Intent: Induction Versus Neoadjuvant Chemotherapy.
Journal: European urology
Published: September 05, 2021
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
Journal: European urology
Published: July 10, 2021
Last Updated: 09/26/2026